<![CDATA[TKI axitinib beats anti-VEGF therapy in wet AMD in phase 3 trial | ASRS 2026]]>
Patients with wet age-related macular degeneration (AMD) treated with a sustained-release formulation of the tyrosine kinase inhibitor (TKI) axitinib were able to spread out their injections by up to nine months, according to data from a phase 3 trial …